Literature DB >> 33396374

Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.

Bryce J B Nelson1, Jan D Andersson1,2, Frank Wuest1.   

Abstract

This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.

Entities:  

Keywords:  actinium-225; alpha particle therapy; astatine-211; bismuth-213; radium-223; targeted alpha therapy; targeted radionuclide therapy; terbium-149; theranostics; thorium-227

Year:  2020        PMID: 33396374      PMCID: PMC7824049          DOI: 10.3390/pharmaceutics13010049

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  110 in total

1.  Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.

Authors:  Ruby Meredith; Julien Torgue; Sui Shen; Darrell R Fisher; Eileen Banaga; Patty Bunch; Desiree Morgan; Jinda Fan; J Michael Straughn
Journal:  J Nucl Med       Date:  2014-08-25       Impact factor: 10.057

2.  Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors:  Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

3.  Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept.

Authors:  Richard P Baum; Thomas Langbein; Aviral Singh; Mostafa Shahinfar; Christiane Schuchardt; Gerd Fabian Volk; Harshad Kulkarni
Journal:  Nucl Med Mol Imaging       Date:  2018-01-11

4.  Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Hirohisa Nakamae; Yun Chen; Donald K Hamlin; Erlinda B Santos; Brian T Kornblit; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2012-02-10       Impact factor: 4.774

5.  Efforts to control the errant products of a targeted in vivo generator.

Authors:  Jaspreet Singh Jaggi; Barry J Kappel; Michael R McDevitt; George Sgouros; Carlos D Flombaum; Catalina Cabassa; David A Scheinberg
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

6.  The treatment of solid tumors by alpha emitters released from (224)Ra-loaded sources-internal dosimetry analysis.

Authors:  L Arazi; T Cooks; M Schmidt; Y Keisari; I Kelson
Journal:  Phys Med Biol       Date:  2010-02-02       Impact factor: 3.609

7.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 8.  177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.

Authors:  Satya Das; Taymeyah Al-Toubah; Ghassan El-Haddad; Jonathan Strosberg
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2019-10-30       Impact factor: 3.869

9.  Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics.

Authors:  Cristina Müller; Christiaan Vermeulen; Ulli Köster; Karl Johnston; Andreas Türler; Roger Schibli; Nicholas P van der Meulen
Journal:  EJNMMI Radiopharm Chem       Date:  2016-03-28

10.  ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.

Authors:  C Kratochwil; F L Giesel; F Bruchertseifer; W Mier; C Apostolidis; R Boll; K Murphy; U Haberkorn; A Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-29       Impact factor: 9.236

View more
  16 in total

1.  H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy.

Authors:  Karthika J Kadassery; A Paden King; Stanley Fayn; Kwamena E Baidoo; Samantha N MacMillan; Freddy E Escorcia; Justin J Wilson
Journal:  Bioconjug Chem       Date:  2022-06-07       Impact factor: 6.069

2.  Core-shell structured gold nanoparticles as carrier for 166Dy/166Ho in vivo generator.

Authors:  Runze Wang; Bernard Ponsard; Hubert Wolterbeek; Antonia Denkova
Journal:  EJNMMI Radiopharm Chem       Date:  2022-07-19

Review 3.  Uranium: The Nuclear Fuel Cycle and Beyond.

Authors:  Bárbara Maria Teixeira Costa Peluzo; Elfi Kraka
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

Review 4.  Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.

Authors:  Neil Grey; Michael Silosky; Christopher H Lieu; Bennett B Chin
Journal:  World J Gastroenterol       Date:  2022-05-07       Impact factor: 5.374

Review 5.  The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules.

Authors:  Yona Keisari; Itzhak Kelson
Journal:  Cells       Date:  2021-01-25       Impact factor: 6.600

Review 6.  PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.

Authors:  Sashi Debnath; Ning Zhou; Mark McLaughlin; Samuel Rice; Anil K Pillai; Guiyang Hao; Xiankai Sun
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

7.  A Novel Single-Step-Labeled 212Pb-CaCO3 Microparticle for Internal Alpha Therapy: Preparation, Stability, and Preclinical Data from Mice.

Authors:  Ruth Gong Li; Kim Lindland; Tina Bjørnlund Bønsdorff; Sara Westrøm; Roy Hartvig Larsen
Journal:  Materials (Basel)       Date:  2021-11-23       Impact factor: 3.623

8.  Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.

Authors:  Matteo Bauckneht; Rita Lai; Francesca D'Amico; Alberto Miceli; Maria Isabella Donegani; Cristina Campi; Daniela Schenone; Stefano Raffa; Silvia Chiola; Francesco Lanfranchi; Sara Elena Rebuzzi; Elisa Zanardi; Malvina Cremante; Cecilia Marini; Giuseppe Fornarini; Silvia Morbelli; Michele Piana; Gianmario Sambuceti
Journal:  Ann Nucl Med       Date:  2022-01-19       Impact factor: 2.668

Review 9.  Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery.

Authors:  Vaishali Kapoor; Abhay K Singh; Calvin D Lewis; Sapna Deore; Dennis E Hallahan
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

10.  First In Vivo and Phantom Imaging of Cyclotron-Produced 133La as a Theranostic Radionuclide for 225Ac and 135La.

Authors:  Bryce J B Nelson; Simon Ferguson; Melinda Wuest; John Wilson; M John M Duke; Susan Richter; Hans Soenke-Jans; Jan D Andersson; Freimut Juengling; Frank Wuest
Journal:  J Nucl Med       Date:  2021-08-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.